Show simple item record

Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer

dc.contributor.authorvan Golen, Kenneth L.en_US
dc.contributor.authorWei Bao, Lien_US
dc.contributor.authorPan, Quintinen_US
dc.contributor.authorMiller, Fred R.en_US
dc.contributor.authorFen Wu, Zhien_US
dc.contributor.authorMerajver, Sofia D.en_US
dc.date.accessioned2006-09-08T20:29:57Z
dc.date.available2006-09-08T20:29:57Z
dc.date.issued2002-05en_US
dc.identifier.citationvan Golen, Kenneth L.; Wei Bao, Li; Pan, Quintin; Miller, Fred R.; Fen Wu, Zhi; Merajver, Sofia D.; (2002). "Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer." Clinical & Experimental Metastasis 19(4): 301-311. <http://hdl.handle.net/2027.42/42584>en_US
dc.identifier.issn0262-0898en_US
dc.identifier.issn1573-7276en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/42584
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12090470&dopt=citationen_US
dc.description.abstractInflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer known. IBC carries a guarded prognosis primarily due to rapid onset of disease, typically within six months, and the propensity of tumor emboli to invade the dermal lymphatics and spread systemically. Although the clinical manifestations of IBC have been well documented, until recently little was known about the genetic mechanisms underlying the disease. In a comprehensive study aimed at identifying the molecular mechanisms responsible for the unique IBC phenotype, our laboratory identified overexpression of RhoC GTPase in over 90% of IBC tumors in contrast to 36% of stage-matched non-IBC tumors. We also demonstrated that overexpression of RhoC GTPase in human mammary epithelial (HME) cells nearly recapitulated the IBC phenotype with regards to invasion, motility and angiogenesis. In the current study we sought to delineate which signaling pathways were responsible for each aspect of the IBC phenotype. Using well-established inhibitors to the mitogen activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways. We found that activation of the MAPK pathway was responsible for motility, invasion and production of angiogenic factors. In contrast, growth under anchorage independent conditions was dependent on the PI3K pathway.en_US
dc.format.extent247176 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherCancer Researchen_US
dc.subject.otherOncologyen_US
dc.subject.otherHematologyen_US
dc.subject.otherSurgical Oncologyen_US
dc.subject.otherAngiogenic Factorsen_US
dc.subject.otherC3 Exotransferaseen_US
dc.subject.otherHuman Mammary Epithelial (HME) Cellsen_US
dc.subject.otherInflammatory Breast Cancer (IBC)en_US
dc.subject.otherInhibitorsen_US
dc.subject.otherInvasionen_US
dc.subject.otherMitogen Activated Protein Kinase (MAPK)en_US
dc.subject.otherMotilityen_US
dc.subject.otherPhosphatidylinositol-3 Kinase (PI3K)en_US
dc.subject.otherRhoC GTPaseen_US
dc.titleMitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, , University of Michigan Comprehensive Cancer Center, , , Ann Arbor, , Michigan, , USA,en_US
dc.contributor.affiliationumDepartment of Internal Medicine, , University of Michigan Comprehensive Cancer Center, , , Ann Arbor, , Michigan, , USA,en_US
dc.contributor.affiliationumDepartment of Internal Medicine, , University of Michigan Comprehensive Cancer Center, , , Ann Arbor, , Michigan, , USA,en_US
dc.contributor.affiliationumDepartment of Internal Medicine, , University of Michigan Comprehensive Cancer Center, , , Ann Arbor, , Michigan, , USA,en_US
dc.contributor.affiliationumDepartment of Internal Medicine, , University of Michigan Comprehensive Cancer Center, , , Ann Arbor, , Michigan, , USA,en_US
dc.contributor.affiliationotherBreast Cancer Program, , Barbara Ann Karmanos Cancer Institute, , , Detroit, , Michigan, , USA,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12090470en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/42584/1/10585_2004_Article_397672.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1015518114931en_US
dc.identifier.sourceClinical & Experimental Metastasisen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.